


## LETTER TO EDITOR

## Why SARS-CoV-2 vaccination still matters in Africa

S.D. Taylor-Robinson <sup>1,2</sup> M.Y. Morgan<sup>3</sup>, C.W. Spearman<sup>4</sup>, A.A.A. Suliman<sup>5,6</sup>, T. Corrah<sup>7</sup>, O.O. Oleribe<sup>8</sup> and A.W. Taylor-Robinson<sup>9,10</sup>

From the Department of Surgery and Cancer, St Mary's Hospital Campus, Imperial College London, South Wharf Road, London W2 1NY, United Kingdom, <sup>2</sup>Department of Public Health, Faculty of Health Sciences, Busitema University, P.O. Box 1460, Mbale, Uganda, <sup>3</sup>UCL Institute for Liver & Digestive Health, Department of Medicine, Royal Free Hospital Campus, University College London, Pond St, London NW3 2QG, United Kingdom, <sup>4</sup>Division of Hepatology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, K Floor, K46 Room 51, Old Main Building, Groote Schuur Hospital, Anzio Rd, Observatory, Republic of South Africa 7925, <sup>5</sup>Department of Medicine, Faculty of Medicine, University of Khartoum, 112 Al Qasr Avenue, Khartoum, Sudan, <sup>6</sup>Department of Cardiology, Shab Teaching Hospital, Army Avenue, Khartoum, Sudan, <sup>7</sup>The Africa Research Excellence Fund, MRC The Gambia @ LSHTM, Atlantic Boulevard, Serrekunda, The Gambia, <sup>8</sup>Office of the Director General, Nigerian Institute of Medical Research, 6 Edmund Crescent, Yaba 101245, Lagos, Nigeria, <sup>9</sup>College of Health Sciences, Vin University, Đa Tôn, Gia Lâm District, Hanoi, Vietnam and <sup>10</sup>Center for Global Health, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, Pennsylvania, PA 19104, USA

Address correspondence to Dr S.D. Taylor-Robinson, Department of Surgery and Cancer, St Mary's Hospital Campus, Imperial College London, London, UK. email: Cstr338333@gmail.com

We are now 2 years into the pandemic caused by SARS-CoV-2 infection. The virus has spread globally to all countries and territories, excepting a few isolated Pacific islands where entry criteria have remained strict. Africa was relatively spared from the magnitude of confirmed infections and deaths experienced in other parts of the world in the initial stages of the pandemic,<sup>1</sup> a situation that has not been maintained more recently.<sup>2</sup> The upsurge in clinical case reports in the latter half of 2021 has brought into sharp relief the pressing need for the continent not to be lapped in the race to vaccinate the global community.

While SARS-CoV-2 vaccination campaigns to lessen the effects of the coronavirus disease 2019 (COVID-19) pandemic have been implemented in the Global North, a combination of irregular and insufficient vaccine supply, a lack of resources to deliver doses and vaccine hesitancy has led to poor vaccine uptake in many parts of Africa. This is compounded by the fact that pharmaceutical companies have often delivered stocks of vaccines that are surplus to the requirements of industrialized nations, often with short expiry dates, to countries where there

is inadequate infrastructure to distribute and administer these on time, if at all.<sup>3</sup>

Vaccine skepticism is growing on the continent, owing to the perception that they 'do not work' and therefore that the need for vaccination is somehow obviated. The notion that it is better to contract the virus for stronger immunity is prevalent in many African countries. However, lessons can be drawn from the other six coronaviruses known to infect mankind, four of which cause the common cold.<sup>4</sup> The immunodominant spike proteins of these common cold viruses constantly mutate, as a result of which, prolonged natural immunity to them is limited.<sup>4</sup> We know that SARS-CoV-2 is also rapidly mutating, more easily in unvaccinated populations. This has recently been highlighted by the emergence of the now globally predominant omicron variant, which first came to light in southern Africa.<sup>5</sup>

We argue that the key public health message that should be conveyed by health authorities and governments across Africa is that rather than being completely preventative, SARS-CoV-2 vaccination is critically important to whole communities. This is

Submitted: 13 January 2022

© The Author(s) 2022. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved.

For permissions, please email: [journals.permissions@oup.com](mailto:journals.permissions@oup.com)

because immunization acts to lessen the severity of COVID-19 infection at the level of the individual while reducing the transmission risk and thereby the potential pool for viral variants to develop at the population level.<sup>6</sup>

As with other coronaviruses, herd immunity to SARS-CoV-2 is unlikely to develop naturally, because of the innate capacity of all coronaviruses to consistently and rapidly evolve, rendering any prevailing immune response less effective.<sup>4</sup> We suggest that while many, if not most, of the viral variants generated are of little clinical significance, it is probable that there will be further SARS-CoV-2 outbreaks due to 'variants of concern' arising for some time to come.<sup>5</sup>

Although eschewed by many, vaccination serves a role to contain viral exposure and thus limit the potential for yet more outbreaks. Of note, as of October 2021, only 77 million people had been double vaccinated in Africa, which is less than 6% of the total population of fast approaching 1.4 billion.<sup>7,8</sup> We urge the governments of African nations not to relax their resolve to vaccinate their populations, as hospital admissions and deaths can potentially be prevented. In this regard, we support the mechanisms for equitable access to SARS-CoV-2 vaccines provided by the strategic partnership of the African Vaccine Acquisition Task Team of the African Union and the WHO-led COVID-19 Vaccines Global Access initiative.<sup>9</sup> However, this alliance is increasingly reliant on fundraising initiatives and private donations and requires much greater global support.

## Funding

None declared.

Conflict of interest. None declared.

## References

1. Oleribe OO, Suliman AAA, Taylor-Robinson SD, Corrah T. Possible reasons why sub-Saharan Africa experienced a less severe COVID-19 pandemic in 2020. *J Multidiscip Healthc* 2021; **14**:3267–71.
2. <https://www.afro.who.int/news/africa-clocks-fastest-surge-covid-19-cases-year-deaths-remain-low> (13 January 2022, date last accessed).
3. <https://www.reuters.com/business/healthcare-pharmaceuticals/exclusive-up-1-million-covid-vaccines-wasted-nigeria-last-month-2021-12-08/> (13 January 2022, date last accessed).
4. Asha K, Khanna M, Kumar B. Current insights into the host immune response to respiratory viral infections. *Adv Exp Med Biol* 2021; **1313**:59–83.
5. Fantini J, Yahi N, Colson P, Chahinian H, La Scola B, Raoult D. The puzzling mutational landscape of the SARS-2-variant Omicron. *J Med Virol* 2022; doi: 10.1002/jmv.27577.
6. Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, et al. The biological and clinical significance of emerging SARS-CoV-2 variants. *Nat Rev Genet* 2021; **22**:757–73.
7. WHO Regional Office for Africa. <https://www.afro.who.int/health-topics/coronavirus-covid-19/vaccines> (13 January 2022, date last accessed).
8. <https://www.afro.who.int/news/less-10-african-countries-hit-key-covid-19-vaccination-goal> (13 January 2022, date last accessed).
9. <https://www.gavi.org> (13 January 2022, date last accessed).